Biomarker-based approaches for assessing alcohol use disorders

International Journal of Environmental Research and Public Health

Volumn 13, Issue 2, 2016, Pages

  Niemelä, Onni ^a  

^a SEINÄJOKI CENTRAL HOSPITAL   (Finland)

Author keywords

Aminotransferase; CDT; Ethanol; Fibrosis; GGT; Health; NASH; Obesity; Oxidative stress

Indexed keywords

ALANINE AMINOTRANSFERASE; ALCOHOL; BIOLOGICAL MARKER; ETHYL GLUCURONIDE; GAMMA GLUTAMYLTRANSFERASE; LIVER ENZYME; TRANSFERRIN; CARBOHYDRATE-DEFICIENT TRANSFERRIN; GLUCURONIC ACID;

ALCOHOL; ASSESSMENT METHOD; BIOMARKER; DRINKING; ETHANOL;

AGE; ALCOHOL CONSUMPTION; ALCOHOL USE DISORDER; COMORBIDITY; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; ENZYME ACTIVITY; EXERCISE; FIBROGENESIS; FOOD INTAKE; HUMAN; INSULIN RESISTANCE; LIFESTYLE; LIVER DYSFUNCTION; METABOLIC SYNDROME X; MORBIDITY; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PROGNOSIS; QUESTIONNAIRE; REFERENCE VALUE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; SEX DIFFERENCE; TISSUE INJURY; VASCULAR DISEASE; WEIGHT GAIN; ALCOHOL-RELATED DISORDERS; ALCOHOLISM; ANALOGS AND DERIVATIVES; BLOOD; BODY MASS; DRINKING BEHAVIOR; EARLY DIAGNOSIS; ENZYMOLOGY; LIVER; LIVER DISEASE; LIVER FUNCTION TEST; METABOLISM; PATHOPHYSIOLOGY;

ALANINE TRANSAMINASE; ALCOHOL DRINKING; ALCOHOL-RELATED DISORDERS; ALCOHOLISM; BIOMARKERS; BODY MASS INDEX; EARLY DIAGNOSIS; GAMMA-GLUTAMYLTRANSFERASE; GLUCURONATES; HUMANS; LIVER; LIVER DISEASES; LIVER FUNCTION TESTS; REFERENCE VALUES; SURVEYS AND QUESTIONNAIRES; TRANSFERRIN;

EID: 84956816008     PISSN: 16617827     EISSN: 16604601     Source Type: Journal    
DOI: 10.3390/ijerph13020166     Document Type: Review

References (159)

1. Connor, J.P.; Haber, P.S.; Hall, W.D. Alcohol use disorders. Lancet 2015. [CrossRef]
2. Leon, D.A.; McCambridge, J. Liver cirrhosis mortality rates in Britain from 1950 to 2002: An analysis of routine data. Lancet 2006, 367, 52–56.[PubMed]
3. Lieber, C.S. Medical disorders of alcoholism. N. Engl. J. Med. 1995, 333, 1058–1065.[PubMed]
4. Rehm, J.; Samokhvalov, A.V.; Shield, K.D. Global burden of alcoholic liver diseases. J. Hepatol. 2013, 59, 160–168.[CrossRef] [PubMed]
5. Wang, F.S.; Fan, J.G.; Zhang, Z.; Gao, B.; Wang, H.Y. The global burden of liver disease: The major impact of China. Hepatology 2014, 60, 2099–2108.[CrossRef] [PubMed]
6. Corrao, G.; Bagnardi, V.; Zambon, A.; La, V.C. A meta-analysis of alcohol consumption and the risk of 15 diseases. Prev. Med. 2004, 38, 613–619.[CrossRef] [PubMed]
7. Gunzerath, L.; Faden, V.; Zakhari, S.; Warren, K. National institute on alcohol abuse and alcoholism report on moderate drinking. Alcohol Clin. Exp. Res. 2004, 28, 829–847.[CrossRef] [PubMed]
8. Van Faassen, E.; Niemelä, O. Biochemistry of Prenatal Alcohol Exposure; Nova Science Publishers: New York, NY, USA, 2011.
9. Alatalo, P.I.; Koivisto, H.M.; Hietala, J.P.; Puukka, K.S.; Bloigu, R.; Niemelä, O.J. Effect of moderate alcohol consumption on liver enzymes increases with increasing body mass index. Am. J. Clin. Nutr. 2008, 88, 1097–1103.[PubMed]
10. Breitling, L.P.; Raum, E.; Müller, H.; Rothenbacher, D.; Brenner, H. Synergism between smoking and alcohol consumption with respect to serum gamma-glutamyltransferase. Hepatology 2009, 49, 802–808.[CrossRef] [PubMed]
11. Jou, J.; Choi, S.S.; Diehl, A.M. Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin. Liver Dis. 2008, 28, 370–379.[CrossRef] [PubMed]
12. Missiha, S.B.; Ostrowski, M.; Heathcote, E.J. Disease progression in chronic hepatitis C: Modifiable and nonmodifiable factors. Gastroenterology 2008, 134, 1699–1714.[CrossRef] [PubMed]
13. Wu, D.; Cederbaum, A.I. Oxidative stress and alcoholic liver disease. Semin. Liver Dis. 2009, 29, 141–154.[CrossRef] [PubMed]
14. Yki-Järvinen, H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014, 2, 901–910. [CrossRef]
15. Chalasani, N.; Younossi, Z.; Lavine, J.E.; Diehl, A.M.; Brunt, E.M.; Cusi, K.; Charlton, M.; Sanyal, A.J. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012, 55, 2005–2023.[CrossRef] [PubMed]
16. Rehm, J.; Gmel, G.; Probst, C.; Shield, K.D. Lifetime-Risk of Alcohol-Attributable Mortality Based on Different Levels of Alcohol Consumption in Seven European Countries. Implications for Low-Risk Drinking Guidelines. Available online: http://www.camh.ca/en/research/news_and_publications/reports_and_books/Documents/Lifetime%20Risk%20of%20Alcohol-Attributable%20Mortality.pdf (accessed on 14 January 2016).
17. Niemelä, O. Biomarkers in alcoholism. Clin. Chim. Acta 2007, 377, 39–49.[CrossRef] [PubMed]
18. Niemelä, O.; Alatalo, P. Biomarkers of alcohol consumption and related liver disease. Scand. J. Clin. Lab. Invest. 2010, 70, 305–312.[CrossRef] [PubMed]
19. O’Shea, R.S.; Dasarathy, S.; McCullough, A.J.; Practice guideline committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Alcoholic liver disease. Hepatology 2010, 51, 307–328.
20. Rockey, D.C.; Bissell, D.M. Noninvasive measures of liver fibrosis. Hepatology 2006, 43, S113–S120.[CrossRef] [PubMed]
21. Rosman, A.S.; Lieber, C.S. Diagnostic utility of laboratory tests in alcoholic liver disease. Clin. Chem. 1994, 40, 1641–1651.[PubMed]
22. Pletcher, M.J.; Pignone, M. Evaluating the clinical utility of a biomarker: A review of methods for estimating health impact. Circulation 2011, 123, 1116–1124.[CrossRef] [PubMed]
23. Cabarcos, P.; Álvarez, I.; Tabernero, M.J.; Bermejo, A.M. Determination of direct alcohol markers: A review. Anal. Bioanal. Chem. 2015, 407, 4907–4925.[CrossRef] [PubMed]
24. Aalto, M.; Alho, H.; Halme, J.T.; Seppä, K. AUDIT and its abbreviated versions in detecting heavy and binge drinking in a general population survey. Drug Alcohol Depend. 2009, 103, 25–29.[CrossRef] [PubMed]
25. Leeman, R.F.; Heilig, M.; Cunningham, C.L.; Stephens, D.N.; Duka, T.; O’Malley, S.S. Ethanol consumption: How should we measure it? Achieving consilience between human and animal phenotypes. Addict. Biol. 2010, 15, 109–124.[CrossRef] [PubMed]
26. Savola, O.; Niemelä, O.; Hillbom, M. Blood alcohol is the best indicator of hazardous alcohol drinking in young adults and working-age patients with trauma. Alcohol Alcohol. 2004, 39, 340–345.[CrossRef] [PubMed]
27. Gutierrez, H.L.; Hund, L.; Shrestha, S.; Rayburn, W.F.; Leeman, L.; Savage, D.D.; Bakhireva, L.N. Ethylglucuronide in maternal hair as a biomarker of prenatal alcohol exposure. Alcohol 2015, 49, 617–623.[CrossRef] [PubMed]
28. Helander, A.; Böttcher, M.; Fehr, C.; Dahmen, N.; Beck, O. Detection times for urinary ethyl glucuronide and ethyl sulfate in heavy drinkers during alcohol detoxification. Alcohol Alcohol. 2009, 44, 55–61.[CrossRef] [PubMed]
29. Joya, X.; Marchei, E.; Salat-Batlle, J.; Garcia-Algar, O.; Calvaresi, V.; Pacifici, R.; Pichini, S. Fetal exposure to ethanol: Relationship between ethyl glucuronide in maternal hair during pregnancy and ethyl glucuronide in neonatal meconium. Clin. Chem. Lab. Med. 2015.[CrossRef] [PubMed]
30. Rainio, J.; Ahola, S.; Kangastupa, P.; Kultti, J.; Tuomi, H.; Karhunen, P.J.; Helander, A.; Niemelä, O. Comparison of ethyl glucuronide and carbohydrate-deficient transferrin in different body fluids for post-mortem identification of alcohol use. Alcohol Alcohol. 2014, 49, 55–59.[CrossRef] [PubMed]
31. Berger, L.; Fendrich, M.; Jones, J.; Fuhrmann, D.; Plate, C.; Lewis, D. Ethyl glucuronide in hair and fingernails as a long-term alcohol biomarker. Addiction 2014, 109, 425–431.[CrossRef] [PubMed]
32. Lees, R.; Kingston, R.; Williams, T.M.; Henderson, G.; Lingford-Hughes, A.; Hickman, M. Comparison of ethyl glucuronide in hair with self-reported alcohol consumption. Alcohol Alcohol. 2012, 47, 267–272.[CrossRef] [PubMed]
33. Himes, S.K.; Dukes, K.A.; Tripp, T.; Petersen, J.M.; Raffo, C.; Burd, L.; Odendaal, H.; Elliott, A.J.; Hereld, D.; Signore, C.; et al. Clinical sensitivity and specificity of meconium fatty acid ethyl ester, ethyl glucuronide, and ethyl sulfate for detecting maternal drinking during pregnancy. Clin. Chem. 2015, 61, 523–532.[CrossRef] [PubMed]
34. Pragst, F.; Yegles, M. Determination of Fatty Acid Ethyl Esters (FAEE) and Ethyl Glucuronide (EtG) in hair: A promising way for retrospective detection of alcohol abuse during pregnancy? Ther. Drug Monit. 2008, 30, 255–263.[CrossRef] [PubMed]
35. Staufer, K.; Andresen, H.; Vettorazzi, E.; Tobias, N.; Nashan, B.; Sterneck, M. Urinary ethyl glucuronide as a novel screening tool in patients pre- and post-liver transplantation improves detection of alcohol consumption. Hepatology 2011, 54, 1640–1649.[CrossRef] [PubMed]
36. Dahl, H.; Hammarberg, A.; Franck, J.; Helander, A. Urinary ethyl glucuronide and ethyl sulfate testing for recent drinking in alcohol-dependent outpatients treated with acamprosate or placebo. Alcohol Alcohol. 2011, 46, 553–557.[CrossRef] [PubMed]
37. Jatlow, P.I.; Agro, A.; Wu, R.; Nadim, H.; Toll, B.A.; Ralevski, E.; Nogueira, C.; Shi, J.; Dziura, J.D.; Petrakis, I.L.; et al. Ethyl glucuronide and ethyl sulfate assays in clinical trials, interpretation, and limitations: Results of a dose ranging alcohol challenge study and 2 clinical trials. Alcohol Clin. Exp. Res. 2014, 38, 2056–2065.[CrossRef] [PubMed]
38. Nissinen, A.E.; Mäkelä, S.M.; Vuoristo, J.T.; Liisanantti, M.K.; Hannuksela, M.L.; Hörkkö, S.; Savolainen, M.J. Immunological detection of in vitro formed phosphatidylethanol—An alcohol biomarker—With monoclonal antibodies. Alcohol Clin. Exp. Res. 2008, 32, 921–928.[CrossRef] [PubMed]
39. Piano, M.R.; Tiwari, S.; Nevoral, L.; Phillips, S.A. Phosphatidylethanol levels are elevated and correlate strongly with AUDIT scores in young adult binge drinkers. Alcohol Alcohol. 2015, 50, 519–525.[CrossRef] [PubMed]
40. Zheng, Y.; Beck, O.; Helander, A. Method development for routine liquid chromatography-mass spectrometry measurement of the alcohol biomarker phosphatidylethanol (PEth) in blood. Clin. Chim. Acta 2011, 412, 1428–1435.[CrossRef] [PubMed]
41. Bakhireva, L.N.; Shrestha, S.; Gutierrez, H.L.; Berry, M.; Schmitt, C.; Sarangarm, D. Stability of phosphatidylethanol in dry blood spot cards. Alcohol Alcohol. 2015.[CrossRef] [PubMed]
42. De Giovanni, N.; Donadio, G.; Chiarotti, M. The reliability of fatty acid ethyl esters (FAEE) as biological markers for the diagnosis of alcohol abuse. J. Anal. Toxicol. 2007, 31, 93–97.[CrossRef] [PubMed]
43. Guo, R.; Ren, J. Alcohol and acetaldehyde in public health: From marvel to menace. Int. J. Environ. Res. Public Health 2010, 7, 1285–1301.[CrossRef] [PubMed]
44. Freeman, T.L.; Tuma, D.J.; Thiele, G.M.; Klassen, L.W.; Worrall, S.; Niemela, O.; Parkkila, S.; Emery, P.W.; Preedy, V.R. Recent advances in alcohol-induced adduct formation. Alcohol Clin. Exp. Res. 2005, 29, 1310–1316.[CrossRef] [PubMed]
45. Hietala, J.; Koivisto, H.; Latvala, J.; Anttila, P.; Niemelä, O. IgAs against acetaldehyde-modified red cell protein as a marker of ethanol consumption in male alcoholic subjects, moderate drinkers, and abstainers. Alcohol Clin. Exp. Res. 2006, 30, 1693–1698.[CrossRef] [PubMed]
46. Niemelä, O. Distribution of ethanol-induced protein adducts in vivo: Relationship to tissue injury. Free Radic. Biol. Med. 2001, 31, 1533–1538. [CrossRef]
47. Jeppsson, J.O.; Arndt, T.; Schellenberg, F.; Wielders, J.P.; Anton, R.F.; Whitfield, J.B.; Helander, A. Toward standardization of carbohydrate-deficient transferrin (CDT) measurements: I. Analyte definition and proposal of a candidate reference method. Clin. Chem. Lab. Med. 2007, 45, 558–562.[CrossRef] [PubMed]
48. Anton, R.F.; Lieber, C.; Tabakoff, B. Carbohydrate-deficient transferrin and gamma-glutamyltransferase for the detection and monitoring of alcohol use: Results from a multisite study. Alcohol Clin. Exp. Res. 2002, 26, 1215–1222.[CrossRef] [PubMed]
49. Romppanen, J.; Punnonen, K.; Anttila, P.; Jakobsson, T.; Blake, J.; Niemelä, O. Serum sialic acid as a marker of alcohol consumption: Effect of liver disease and heavy drinking. Alcohol Clin. Exp. Res. 2002, 26, 1234–1238.[CrossRef] [PubMed]
50. Chrostek, L.; Cylwik, B.; Krawiec, A.; Korcz, W.; Szmitkowski, M. Relationship between serum sialic acid and sialylated glycoproteins in alcoholics. Alcohol Alcohol. 2007, 42, 588–592.[CrossRef] [PubMed]
51. Viitala, K.; Lähdesmäki, K.; Niemelä, O. Comparison of the Axis %CDT TIA and the CDTect method as laboratory tests of alcohol abuse. Clin. Chem. 1998, 44, 1209–1215.[PubMed]
52. Burke, V.; Puddey, I.B.; Rakic, V.; Swanson, N.R.; Dimmitt, S.B.; Beilin, L.J.; Ching, S.; Beilby, J.P. Carbohydrate-deficient transferrin as a marker of change in alcohol intake in men drinking 20 to 60 g of alcohol per day. Alcohol Clin. Exp. Res. 1998, 22, 1973–1980.[CrossRef] [PubMed]
53. Mikkelsen, I.M.; Kanitz, R.D.; Nilssen, O.; Huseby, N.E. Carbohydrate-deficient transferrin: Marker of actual alcohol consumption or chronic alcohol misuse? Alcohol Alcohol. 1998, 33, 646–650.[CrossRef] [PubMed]
54. Schmidt, L.G.; Schmidt, K.; Dufeu, P.; Ohse, A.; Rommelspacher, H.; Muller, C. Superiority of carbohydrate-deficient transferrin to gamma-glutamyltransferase in detecting relapse in alcoholism. Am. J. Psychiatry 1997, 154, 75–80.[PubMed]
55. Giannini, E.G.; Testa, R.; Savarino, V. Liver enzyme alteration: A guide for clinicians. CMAJ 2005, 172, 367–379.[CrossRef] [PubMed]
56. Whitfield, J.B. Gamma glutamyl transferase. Crit. Rev. Clin. Lab. Sci. 2001, 38, 263–355.[CrossRef] [PubMed]
57. Salaspuro, M. Carbohydrate-deficient transferrin as compared to other markers of alcoholism: A systematic review. Alcohol 1999, 19, 261–271. [CrossRef]
58. Hietala, J.; Koivisto, H.; Anttila, P.; Niemelä, O. Comparison of the combined marker GGT-CDT and the conventional laboratory markers of alcohol abuse in heavy drinkers, moderate drinkers and abstainers. Alcohol Alcohol. 2006, 41, 528–533.[CrossRef] [PubMed]
59. Latvala, J.; Parkkila, S.; Niemelä, O. Excess alcohol consumption is common in patients with cytopenia: Studies in blood and bone marrow cells. Alcohol Clin. Exp. Res. 2004, 28, 619–624.[CrossRef] [PubMed]
60. Koivisto, H.; Hietala, J.; Anttila, P.; Parkkila, S.; Niemelä, O. Long-term ethanol consumption and macrocytosis: Diagnostic and pathogenic implications. J. Lab. Clin. Med. 2006, 147, 191–196.[CrossRef] [PubMed]
61. Lindenbaum, J. Hematologic complications of alcohol abuse. Semin. Liver Dis. 1987, 7, 169–181.[CrossRef] [PubMed]
62. Alatalo, P.I.; Koivisto, H.M.; Hietala, J.P.; Bloigu, R.S.; Niemelä, O.J. Gender-dependent impacts of body mass index and moderate alcohol consumption on serum uric acid—An index of oxidant stress status? Free Radic. Biol. Med. 2009, 46, 1233–1238.[CrossRef] [PubMed]
63. Johnson, R.J.; Rivard, C.; Nakagawa, T.; Sautin, Y.Y.; Sanchez-Lozada, L.G. Uric acid: More to learn, more experiments to do. Am. J. Hypertens. 2009, 22, 952–953.[CrossRef] [PubMed]
64. Kurra, V.; Eräranta, A.; Jolma, P.; Vehmas, T.I.; Riutta, A.; Moilanen, E.; Tahvanainen, A.; Kalliovalkama, J.; Niemelä, O.; Myllymäki, J.; et al. Hyperuricemia, oxidative stress, and carotid artery tone in experimental renal insufficiency. Am. J. Hypertens. 2009, 22, 964–970.[CrossRef] [PubMed]
65. Cali, A.M.; De Oliveira, A.M.; Kim, H.; Chen, S.; Reyes-Mugica, M.; Escalera, S.; Dziura, J.; Taksali, S.E.; Kursawe, R.; Shaw, M.; et al. Glucose dysregulation and hepatic steatosis in obese adolescents: Is there a link? Hepatology 2009, 49, 1896–1903.[CrossRef] [PubMed]
66. Daeppen, J.B.; Smith, T.L.; Schuckit, M.A. Influence of age and body mass index on gamma-glutamyltransferase activity: A 15-year follow-up evaluation in a community sample. Alcohol Clin. Exp. Res. 1998, 22, 941–944.[CrossRef] [PubMed]
67. Lam, G.M.; Mobarhan, S. Central obesity and elevated liver enzymes. Nutr. Rev. 2004, 62, 394–399.[CrossRef] [PubMed]
68. Lawlor, D.A.; Sattar, N.; Smith, G.D.; Ebrahim, S. The associations of physical activity and adiposity with alanine aminotransferase and gamma-glutamyltransferase. Am. J. Epidemiol. 2005, 161, 1081–1088.[CrossRef] [PubMed]
69. Puukka, K.; Hietala, J.; Koivisto, H.; Anttila, P.; Bloigu, R.; Niemelä, O. Additive effects of moderate drinking and obesity on serum gamma-glutamyl transferase activity. Am. J. Clin. Nutr. 2006, 83, 1351–1354.[PubMed]
70. Halsted, C.H. Obesity: Effects on the liver and gastrointestinal system. Curr. Opin. Clin. Nutr. Metab. Care 1999, 2, 425–429.[CrossRef] [PubMed]
71. Ruhl, C.E.; Everhart, J.E. Joint effects of body weight and alcohol on elevated serum alanine aminotransferase in the United States population. Clin. Gastroenterol. Hepatol. 2005, 3, 1260–1268. [CrossRef]
72. Tsai, J.; Ford, E.S.; Zhao, G.; Li, C.; Greenlund, K.J.; Croft, J.B. Co-occurrence of obesity and patterns of alcohol use associated with elevated serum hepatic enzymes in U.S. adults. J. Behav. Med. 2012, 35, 200–210.[CrossRef] [PubMed]
73. Danielsson, J.; Kangastupa, P.; Laatikainen, T.; Aalto, M.; Niemelä, O. Individual and joint impacts of ethanol use, BMI, age and gender on serum gamma-glutamyltransferase levels in healthy volunteers. Int. J. Mol. Sci. 2013, 14, 11929–11941.[CrossRef] [PubMed]
74. Emdin, M.; Pompella, A.; Paolicchi, A. Gamma-glutamyltransferase, atherosclerosis, and cardiovascular disease: Triggering oxidative stress within the plaque. Circulation 2005, 112, 2078–2080.[CrossRef] [PubMed]
75. Finkel, T.; Holbrook, N.J. Oxidants, oxidative stress and the biology of ageing. Nature 2000, 408, 239–247.[CrossRef] [PubMed]
76. Lança, A.J.; Israel, Y. Histochemical demonstration of sinusoidal gamma-glutamyltransferase activity by substrate protection fixation: Comparative studies in rat and guinea pig liver. Hepatology 1991, 14, 857–863.
77. Speisky, H.; Shackel, N.; Varghese, G.; Wade, D.; Israel, Y. Role of hepatic gamma-glutamyltransferase in the degradation of circulating glutathione: Studies in the intact guinea pig perfused liver. Hepatology 1990, 11, 843–849.[CrossRef] [PubMed]
78. Zhang, H.; Forman, H.J. Redox regulation of gamma-glutamyl transpeptidase. Am. J. Respir. Cell Mol. Biol. 2009, 41, 509–515.[CrossRef] [PubMed]
79. Lee, D.H.; Ha, M.H.; Kam, S.; Chun, B.; Lee, J.; Song, K.; Boo, Y.; Steffen, L.; Jacobs, D.R., Jr. A strong secular trend in serum gamma-glutamyltransferase from 1996 to 2003 among South Korean men. Am. J. Epidemiol. 2006, 163, 57–65.[CrossRef] [PubMed]
80. Lee, D.H.; Blomhoff, R.; Jacobs, D.R., Jr. Is serum gamma glutamyltransferase a marker of oxidative stress? Free Radic. Res. 2004, 38, 535–539.[CrossRef] [PubMed]
81. Fentiman, I.S.; Allen, D.S. Gamma-glutamyl transferase and breast cancer risk. Brit. J. Cancer 2010, 103, 90–93.[CrossRef] [PubMed]
82. Franzini, M.; Paolicchi, A.; Fornaciari, I.; Ottaviano, V.; Fierabracci, V.; Maltinti, M.; Ripoli, A.; Zyw, L.; Scatena, F.; Passino, C.; et al. Cardiovascular risk factors and gamma-glutamyltransferase fractions in healthy individuals. Clin. Chem. Lab. Med. 2010, 48, 713–717.[CrossRef] [PubMed]
83. Franzini, M.; Fornaciari, I.; Rong, J.; Larson, M.G.; Passino, C.; Emdin, M.; Paolicchi, A.; Vasan, R.S. Correlates and reference limits of plasma gamma-glutamyltransferase fractions from the Framingham heart study. Clin. Chim. Acta 2013, 417, 19–25.[CrossRef] [PubMed]
84. Fraser, A.; Harris, R.; Sattar, N.; Ebrahim, S.; Davey Smith, G.; Lawlor, D.A. Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: The British women’s heart and health study and meta-analysis. Diabetes Care 2009, 32, 741–750.[CrossRef] [PubMed]
85. Lippi, G.; Targher, G.; Montagnana, M.; Salvagno, G.L.; Guidi, G.C. Relationship between gamma-glutamyltransferase, lipids and lipoprotein(a) in the general population. Clin. Chim. Acta 2007, 384, 163–166.[CrossRef] [PubMed]
86. Strasak, A.M.; Pfeiffer, R.M.; Klenk, J.; Hilbe, W.; Oberaigner, W.; Gregory, M.; Concin, H.; Diem, G.; Pfeiffer, K.P.; Ruttmann, E.; et al. Prospective study of the association of gamma-glutamyltransferase with cancer incidence in women. Int. J. Cancer 2008, 123, 1902–1906.[CrossRef] [PubMed]
87. Sung, K.C.; Ryu, S.; Kim, B.S.; Cheong, E.S.; Park, D.I.; Kim, B.I.; Kwon, M.J.; Wild, S.H.; Byrne, C.D. Gamma-glutamyl transferase is associated with mortality outcomes independently of fatty liver. Clin. Chem. 2015, 61, 1173–1181.[CrossRef] [PubMed]
88. Cao, Y.; Willett, W.C.; Rimm, E.B.; Stampfer, M.J.; Giovannucci, E.L. Light to moderate intake of alcohol, drinking patterns, and risk of cancer: Results from two prospective U.S. cohort studies. BMJ 2015, 351, h4238.[CrossRef] [PubMed]
89. Sipilä, P.; Rose, R.J.; Kaprio, J. Drinking and mortality: Long-term follow-up of drinking-discordant twin pairs. Addiction 2015.[CrossRef] [PubMed]
90. Haring, R.; Wallaschofski, H.; Nauck, M.; Dörr, M.; Baumeister, S.E.; Völzke, H. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels. Hepatology 2009, 50, 1403–1411.[CrossRef] [PubMed]
91. Kazemi-Shirazi, L.; Endler, G.; Winkler, S.; Schickbauer, T.; Wagner, O.; Marsik, C. Gamma glutamyltransferase and long-term survival: Is it just the liver? Clin. Chem. 2007, 53, 940–946. [CrossRef]
92. Ruhl, C.E.; Everhart, J.E. Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population. Gastroenterology 2009, 136, 477–485.[CrossRef] [PubMed]
93. Ruttmann, E.; Brant, L.J.; Concin, H.; Diem, G.; Rapp, K.; Ulmer, H.; The Vorarlberg Health Monitoring and Promotion Program Study Group. Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: An epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation 2005, 112, 2130–2137.[CrossRef] [PubMed]
94. Kozakova, M.; Palombo, C.; Eng, M.P.; Dekker, J.; Flyvbjerg, A.; Mitrakou, A.; Gastaldelli, A.; Ferrannini, E. Fatty liver index, gamma-glutamyltransferase, and early carotid plaques. Hepatology 2012, 55, 1406–1415.[CrossRef] [PubMed]
95. Danielsson, J.; Kangastupa, P.; Laatikainen, T.; Aalto, M.; Niemelä, O. Impacts of common factors of life style on serum liver enzymes. World J. Gastroenterol. 2014, 20, 11743–11752.[CrossRef] [PubMed]
96. Pratt, D.S.; Kaplan, M.M. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N. Engl. J. Med. 2000, 342, 1266–1271.[CrossRef] [PubMed]
97. Brunt, E.M. Nonalcoholic steatohepatitis. Semin. Liver Dis. 2004, 24, 3–20.[PubMed]
98. Clark, J.M.; Brancati, F.L.; Diehl, A.M. The prevalence and etiology of elevated aminotransferase levels in the United States. Am. J. Gastroenterol. 2003, 98, 960–967.[CrossRef] [PubMed]
99. Loomba, R.; Bettencourt, R.; Barrett-Connor, E. Synergistic association between alcohol intake and body mass index with serum alanine and aspartate aminotransferase levels in older adults: The Rancho Bernardo study. Aliment. Pharmacol. Ther. 2009, 30, 1137–1149.[CrossRef] [PubMed]
100. Ioannou, G.N. Implications of elevated serum alanine aminotransferase levels: Think outside the liver. Gastroenterology 2008, 135, 1851–1854.[CrossRef] [PubMed]
101. St George, A.; Bauman, A.; Johnston, A.; Farrell, G.; Chey, T.; George, J. Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology 2009, 50, 68–76.[CrossRef] [PubMed]
102. Ghouri, N.; Preiss, D.; Sattar, N. Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: A narrative review and clinical perspective of prospective data. Hepatology 2010, 52, 1156–1161.[CrossRef] [PubMed]
103. Kim, H.C.; Nam, C.M.; Jee, S.H.; Han, K.H.; Oh, D.K.; Suh, I. Normal serum aminotransferase concentration and risk of mortality from liver diseases: Prospective cohort study. BMJ 2004, 328, 983.[CrossRef] [PubMed]
104. Lee, T.H.; Kim, W.R.; Benson, J.T.; Therneau, T.M.; Melton, L.J., III. Serum aminotransferase activity and mortality risk in a United States community. Hepatology 2008, 47, 880–887.[CrossRef] [PubMed]
105. Lee, D.H.; Jacobs, D.R., Jr.; Gross, M.; Kiefe, C.I.; Roseman, J.; Lewis, C.E.; Steffes, M. Gamma-glutamyltransferase is a predictor of incident diabetes and hypertension: The Coronary Artery Risk Development in Young Adults (CARDIA) study. Clin. Chem. 2003, 49, 1358–1366.[CrossRef] [PubMed]
106. Lee, D.H.; Silventoinen, K.; Hu, G.; Jacobs, D.R., Jr.; Jousilahti, P.; Sundvall, J.; Tuomilehto, J. Serum gamma-glutamyltransferase predicts non-fatal myocardial infarction and fatal coronary heart disease among 28,838 middle-aged men and women. Eur. Heart J. 2006, 27, 2170–2176.[CrossRef] [PubMed]
107. Söderberg, C.; Stål, P.; Askling, J.; Glaumann, H.; Lindberg, G.; Marmur, J.; Hultcrantz, R. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010, 51, 595–602.[CrossRef] [PubMed]
108. Targher, G.; Bertolini, L.; Rodella, S.; Tessari, R.; Zenari, L.; Lippi, G.; Arcaro, G. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 2007, 30, 2119–2121.[CrossRef] [PubMed]
109. Nalpas, B.; Vassault, A.; Le Guillou, A.; Lesgourgues, B.; Ferry, N.; Lacour, B.; Berthelot, P. Serum activity of mitochondrial aspartate aminotransferase: A sensitive marker of alcoholism with or without alcoholic hepatitis. Hepatology 1984, 4, 893–896.[CrossRef] [PubMed]
110. Salaspuro, M. Use of enzymes for the diagnosis of alcohol-related organ damage. Enzyme 1987, 37, 87–107.[PubMed]
111. Sheth, S.G.; Flamm, S.L.; Gordon, F.D.; Chopra, S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am. J. Gastroenterol. 1998, 93, 44–48.[CrossRef] [PubMed]
112. Diehl, A.M.; Potter, J.; Boitnott, J.; Van Duyn, M.A.; Herlong, H.F.; Mezey, E. Relationship between pyridoxal 5’-phosphate deficiency and aminotransferase levels in alcoholic hepatitis. Gastroenterology 1984, 86, 632–636.[PubMed]
113. Angulo, P.; Keach, J.C.; Batts, K.P.; Lindor, K.D. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999, 30, 1356–1362.[CrossRef] [PubMed]
114. Suzuki, A.; Lymp, J.; Sauver, J.S.; Angulo, P.; Lindor, K. Values and limitations of serum aminotransferases in clinical trials of nonalcoholic steatohepatitis. Liver Int. 2006, 26, 1209–1216.[CrossRef] [PubMed]
115. Schenker, S. Medical consequences of alcohol abuse: Is gender a factor? Alcohol Clin. Exp. Res. 1997, 21, 179–181.[PubMed]
116. Tynjälä, J.; Kangastupa, P.; Laatikainen, T.; Aalto, M.; Niemelä, O. Effect of age and gender on the relationship between alcohol consumption and serum GGT: Time to recalibrate goals for normal ranges. Alcohol Alcohol. 2012, 47, 558–562.[CrossRef] [PubMed]
117. Moore, A.A.; Giuli, L.; Gould, R.; Hu, P.; Zhou, K.; Reuben, D.; Greendale, G.; Karlamangla, A. Alcohol use, comorbidity, and mortality. J. Am. Geriatr. Soc. 2006, 54, 757–762.[CrossRef] [PubMed]
118. Fontana, L.; Zhao, E.; Amir, M.; Dong, H.; Tanaka, K.; Czaja, M.J. Aging promotes the development of diet-induced murine steatohepatitis but not steatosis. Hepatology 2013, 57, 995–1004.[CrossRef] [PubMed]
119. Ioannou, G.N.; Morrow, O.B.; Connole, M.L.; Lee, S.P. Association between dietary nutrient composition and the incidence of cirrhosis or liver cancer in the United States population. Hepatology 2009, 50, 175–184.[CrossRef] [PubMed]
120. Tsukamoto, H.; Horne, W.; Kamimura, S.; Niemelä, O.; Parkkila, S.; Ylä-Herttuala, S.; Brittenham, G.M. Experimental liver cirrhosis induced by alcohol and iron. J. Clin. Investig. 1995, 96, 620–630.[CrossRef] [PubMed]
121. Halsted, C.H.; Villanueva, J.A.; Devlin, A.M.; Niemelä, O.; Parkkila, S.; Garrow, T.A.; Wallock, L.M.; Shigenaga, M.K.; Melnyk, S.; James, S.J. Folate deficiency disturbs hepatic methionine metabolism and promotes liver injury in the ethanol-fed micropig. Proc. Natl. Acad. Sci. USA 2002, 99, 10072–10077.[CrossRef] [PubMed]
122. Breitling, L.P.; Arndt, V.; Drath, C.; Brenner, H. Liver enzymes: Interaction analysis of smoking with alcohol consumption or BMI, comparing AST and ALT to gamma-GT. PLoS ONE 2011, 6, e27951.[CrossRef] [PubMed]
123. Danielsson, J.; Kangastupa, P.; Laatikainen, T.; Aalto, M.; Niemelä, O. Dose- and gender-dependent interactions between coffee consumption and serum GGT activity in alcohol consumers. Alcohol Alcohol. 2013, 48, 303–307.[CrossRef] [PubMed]
124. Freedman, N.D.; Park, Y.; Abnet, C.C.; Hollenbeck, A.R.; Sinha, R. Association of coffee drinking with total and cause-specific mortality. N. Engl. J. Med. 2012, 366, 1891–1904.[CrossRef] [PubMed]
125. Xiao, Q.; Sinha, R.; Graubard, B.I.; Freedman, N.D. Inverse associations of total and decaffeinated coffee with liver enzyme levels in National Health and Nutrition Examination Survey 1999–2010. Hepatology 2014, 60, 2091–2098.[CrossRef] [PubMed]
126. Johnson, N.A.; Sachinwalla, T.; Walton, D.W.; Smith, K.; Armstrong, A.; Thompson, M.W.; George, J. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology 2009, 50, 1105–1112.[CrossRef] [PubMed]
127. Ristow, M.; Zarse, K.; Oberbach, A.; Kloting, N.; Birringer, M.; Kiehntopf, M.; Stumvoll, M.; Kahn, C.R.; Bluher, M. Antioxidants prevent health-promoting effects of physical exercise in humans. Proc. Natl. Acad. Sci. USA 2009, 106, 8665–8670.[CrossRef] [PubMed]
128. Room, R.; Babor, T.; Rehm, J. Alcohol and public health. Lancet 2005, 365, 519–530. [CrossRef]
129. Jaakkola, M.; Sillanaukee, P.; Lof, K.; Koivula, T.; Nordback, I. Blood tests for detection of alcoholic cause of acute pancreatitis. Lancet 1994, 343, 1328–1329. [CrossRef]
130. Blake, J.; Orrego, H. Monitoring treatment of alcoholic liver disease: evaluation of various severity indices. Clin. Chem. 1991, 37, 5–13.[PubMed]
131. Arroyo, V. Human serum albumin: Not just a plasma volume expander. Hepatology 2009, 50, 355–357.[CrossRef] [PubMed]
132. Tyulina, O.V.; Prokopieva, V.D.; Boldyrev, A.A.; Johnson, P. Erythrocyte and plasma protein modification in alcoholism: A possible role of acetaldehyde. Biochim. Biophys. Acta 2006, 1762, 558–563.[CrossRef] [PubMed]
133. Alatalo, P.; Koivisto, H.; Puukka, K.; Hietala, J.; Anttila, P.; Bloigu, R.; Niemelä, O. Biomarkers of liver status in heavy drinkers, moderate drinkers and abstainers. Alcohol Alcohol. 2009, 44, 199–203.[CrossRef] [PubMed]
134. Ioannou, G.N.; Dominitz, J.A.; Weiss, N.S.; Heagerty, P.J.; Kowdley, K.V. The effect of alcohol consumption on the prevalence of iron overload, iron deficiency, and iron deficiency anemia. Gastroenterology 2004, 126, 1293–1301.[CrossRef] [PubMed]
135. Bacon, B.R.; Britton, R.S. The pathology of hepatic iron overload: A free radical-mediated process? Hepatology 1990, 11, 127–137.[CrossRef] [PubMed]
136. Fletcher, L.M.; Dixon, J.L.; Purdie, D.M.; Powell, L.W.; Crawford, D.H. Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. Gastroenterology 2002, 122, 281–289.[CrossRef] [PubMed]
137. Lee, D.H.; Jacobs, D.R., Jr. Serum markers of stored body iron are not appropriate markers of health effects of iron: A focus on serum ferritin. Med. Hypotheses 2004, 62, 442–445. [CrossRef]
138. Iredale, J.P. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J. Clin. Investig. 2007, 117, 539–548.[CrossRef] [PubMed]
139. Bataller, R.; Brenner, D.A. Liver fibrosis. J. Clin. Investig. 2005, 115, 209–218.[CrossRef] [PubMed]
140. Poynard, T.; Munteanu, M.; Deckmyn, O.; Ngo, Y.; Drane, F.; Castille, J.M.; Housset, C.; Ratziu, V.; Imbert-Bismut, F. Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: Proof of concept and first application in a large population. J. Hepatol. 2012, 57, 541–548.[CrossRef] [PubMed]
141. Niemelä, O.; Risteli, J.; Blake, J.E.; Risteli, L.; Compton, K.V.; Orrego, H. Markers of fibrogenesis and basement membrane formation in alcoholic liver disease. Relation to severity, presence of hepatitis, and alcohol intake. Gastroenterology 1990, 98, 1612–1619.[PubMed]
142. Koivisto, H.; Hietala, J.; Niemelä, O. An inverse relationship between markers of fibrogenesis and collagen degradation in patients with or without alcoholic liver disease. Am. J. Gastroenterol. 2007, 102, 773–779.[CrossRef] [PubMed]
143. Vidali, M.; Hietala, J.; Occhino, G.; Ivaldi, A.; Sutti, S.; Niemela, O.; Albano, E. Immune responses against oxidative stress-derived antigens are associated with increased circulating tumor necrosis factor-alpha in heavy drinkers. Free Radic. Biol. Med. 2008, 45, 306–311.[CrossRef] [PubMed]
144. Naveau, S.; Gaude, G.; Asnacios, A.; Agostini, H.; Abella, A.; Barri-Ova, N.; Dauvois, B.; Prevot, S.; Ngo, Y.; Munteanu, M.; et al. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology 2009, 49, 97–105.[CrossRef] [PubMed]
145. Tsochatzis, E.A.; Crossan, C.; Longworth, L.; Gurusamy, K.; Rodriguez-Peralvarez, M.; Mantzoukis, K.; O'Brien, J.; Thalassinos, E.; Papastergiou, V.; Noel-Storr, A.; et al. Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C. Hepatology 2014, 60, 832–843.[CrossRef] [PubMed]
146. Parkes, J.; Roderick, P.; Harris, S.; Day, C.; Mutimer, D.; Collier, J.; Lombard, M.; Alexander, G.; Ramage, J.; Dusheiko, G.; et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 2010, 59, 1245–1251.[CrossRef] [PubMed]
147. Sheron, N.; Moore, M.; Ansett, S.; Parsons, C.; Bateman, A. Developing a “traffic light” test with potential for rational early diagnosis of liver fibrosis and cirrhosis in the community. Brit. J. Gen. Pract. 2012, 62, e616–e624.[CrossRef] [PubMed]
148. Tuomi, H.; Kultti, J.; Danielsson, J.; Kangastupa, P.; Åkerman, K.; Niemelä, O. Serum soluble urokinase plasminogen activator receptor in alcoholics: Relation to liver disease severity, fibrogenesis, and alcohol use. J. Gastroenterol. Hepatol. 2014, 29, 1991–1995.[CrossRef] [PubMed]
149. Møller, H.J, Soluble CD 163. Scand. J. Clin. Lab. Investig. 2012, 72, 1–13.[CrossRef] [PubMed]
150. Sandahl, T.D.; Grønbaek, H.; Møller, H.J.; Støy, S.; Thomsen, K.L.; Dige, A.K.; Agnholt, J.; Hamilton-Dutoit, S.; Thiel, S.; Vilstrup, H. Hepatic macrophage activation and the LPS pathway in patients with alcoholic hepatitis: A prospective cohort study. Am. J. Gastroenterol. 2014, 109, 1749–1756.[CrossRef] [PubMed]
151. Kazankov, K.; Barrera, F.; Møller, H.J.; Bibby, B.M.; Vilstrup, H.; George, J.; Grønbaek, H. Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C. Hepatology 2014, 60, 521–530.[CrossRef] [PubMed]
152. Latvala, J.; Hietala, J.; Koivisto, H.; Järvi, K.; Anttila, P.; Niemelä, O. Immune responses to ethanol metabolites and cytokine profiles differentiate alcoholics with or without liver disease. Am. J. Gastroenterol. 2005, 100, 1303–1310.[CrossRef] [PubMed]
153. Niemelä, O.; Parkkila, S.; Ylä-Herttuala, S.; Villanueva, J.; Ruebner, B.; Halsted, C.H. Sequential acetaldehyde production, lipid peroxidation, and fibrogenesis in micropig model of alcohol-induced liver disease. Hepatology 1995, 22, 1208–1214. [CrossRef]
154. Crews, F.T.; Bechara, R.; Brown, L.A.; Guidot, D.M.; Mandrekar, P.; Oak, S.; Qin, L.; Szabo, G.; Wheeler, M.; Zou, J. Cytokines and alcohol. Alcohol Clin. Exp. Res. 2006, 30, 720–730.[CrossRef] [PubMed]
155. Neupane, S.P.; Lien, L.; Martinez, P.; Aukrust, P.; Ueland, T.; Mollnes, T.E.; Hestad, K.; Bramness, J.G. High frequency and intensity of drinking may attenuate increased inflammatory cytokine levels of major depression in alcohol-use disorders. CNS. Neurosci. Ther. 2014, 20, 898–904.[CrossRef] [PubMed]
156. Gluud, C.; Gluud, L.L. Evidence based diagnostics. BMJ 2005, 330, 724–726.[CrossRef] [PubMed]
157. Mu, R.; Chen, W.; Pan, B.; Wang, L.; Hao, X.; Huang, X.; Qiao, R.; Zhao, M.; Zhang, C.; Guo, W.; et al. First definition of reference intervals of liver function tests in China: A large-population-based multi-center study about healthy adults. PLoS ONE 2013, 8, e72916.
158. Ruhl, C.E.; Everhart, J.E. Upper limits of normal for alanine aminotransferase activity in the United States population. Hepatology 2012, 55, 447–454.[CrossRef] [PubMed]
159. Rustad, P.; Felding, P.; Franzson, L.; Kairisto, V.; Lahti, A.; Mårtensson, A.; Hyltoft Petersen, P.; Simonsson, P.; Steensland, H.; Uldall, A. The Nordic Reference Interval Project 2000: Recommended reference intervals for 25 common biochemical properties. Scand. J. Clin. Lab. Investig. 2004, 64, 271–284.[CrossRef] [PubMed]